Vectus Biosystems

Vectus Biosystems EBIT Growth

The Year-over-Year EBIT Growth of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 18.92 %. In the previous year, Year-over-Year EBIT Growth was 25.67 % — a change of -26.29% (lower).

EBIT Growth

18.92 %

YoY

-26.29%

Last updated:

Year-over-Year EBIT Growth of Vectus Biosystems is 2026 18.92 % . Year-over-Year EBIT Growth of Vectus Biosystems was 2025 25.67 % . It decreases by -26.29% lower compared to the previous year.

The Vectus Biosystems EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
40.59 AUD
Jan 1, 2020
-12.22 AUD
Jan 1, 2021
-39.80 AUD
Jan 1, 2022
11.36 AUD
Jan 1, 2023
1.94 AUD
Jan 1, 2024
29.84 AUD
Jan 1, 2025
25.67 AUD
Jan 1, 2026
18.92 AUD
The Vectus Biosystems EBIT Growth history
YEAREBIT GrowthYoY
18.92 %-26.29%
25.67 %-13.98%
29.84 %+1,438.18%
1.94 %-82.93%
11.36 %-128.55%
-39.80 %+225.61%
-12.22 %-130.11%
40.59 %+138.00%
17.05 %-186.43%
-19.73 %-70.63%
-67.18 %+6.75%
-62.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Year-over-Year EBIT Growth of Vectus Biosystems is 18.92 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Vectus Biosystems

All Key Metrics — Vectus Biosystems